Ament P W, Bertolino J G
Latrobe Area Hospital, Pennsylvania.
Am Fam Physician. 1994 Dec;50(8):1763-8.
Enoxaparin, a low-molecular-weigth heparin, has recently been approved for use in the prevention of deep venous thrombosis following elective hip replacement surgery. Clinical trials have demonstrated enoxaparin to be superior to placebo, dextran and unfractionated heparin in deep venous thrombosis prophylaxis. However, no published studies have compared the efficacy of enoxaparin with that of warfarin in the prevention of deep venous thrombosis. Advantages of enoxaparin include less frequent dosing, reduced need for laboratory monitoring and a lower incidence of adverse effects, including hemorrhage. Although enoxaparin is more expensive than unfractionated heparin, its potential benefits may offset its higher cost.
依诺肝素，一种低分子量肝素，最近已被批准用于预防择期髋关节置换术后的深静脉血栓形成。临床试验表明，在预防深静脉血栓方面，依诺肝素优于安慰剂、右旋糖酐和普通肝素。然而，尚无已发表的研究比较依诺肝素与华法林在预防深静脉血栓形成方面的疗效。依诺肝素的优点包括给药频率较低、减少了实验室监测的需求以及不良反应（包括出血）的发生率较低。尽管依诺肝素比普通肝素更昂贵，但其潜在益处可能抵消其较高的成本。
